Ana M. Dias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana M. Dias has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Salomé Soares Pinho
I3S – Institute for Research and Innovation in Health, University of Porto, Porto, Portugal
11 shared publications - Celso Albuquerque Reis
i3S ‐ Instituto de Investigação e Inovação em Saúde Universidade do Porto Porto Portugal
6 shared publications - Sandra Carvalho
International Iberian Nanotechnology Laboratory, Department of Nanoelectronics Engineering, 4715-330 Braga, Portugal
5 shared publications - Márcia Santos Pereira
Department of Translational Rheumatology and Immunology, Institute of Musculoskeletal Medicine, University of Münster, 48149 Münster, Germany
4 shared publications Paula Lago
Department of Gastroenterology, Centro Hospitalar do Porto, Porto, Portugal
4 shared publications- Catarina Rodrigues Almeida
Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
3 shared publications
Latest Publications
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S012-S013
OP13 Glyco-fingerprint as a relevant risk factor on colitis-associated cancer
Background: Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract being considered a serious risk factor for the development of colitis-associated cancer (CAC). However, the molecular mechanisms underlying CAC progression are still elusive. We previously showed that decreased expression of MGAT5 glycogene on intestinal T lymphocytes from UC patients was associated with a hyperimmune response and with disease severity (Dias, AM et al. HMG,2014; Dias, AM et al. PNAS, 2018). On the other hand, we also demonstrated that the aberrant expression of MGAT5 glycogene in gastrointestinal cancer cells was associated with tumour invasiveness and progression (Carvalho S et al., Oncogene 2015). However, whether this differential expression of glycans in colitis and cancer contexts mediated by MGAT5 glycogene constitutes a new mechanism in CAC remains completely unknown. Methods: A well-characterised cohort of paraffin samples from CAC patients at different stages of carcinogenesis (colitis; dysplasia and colon cancer) were evaluated by immunohistochemistry, using specific lectins to evaluate the N-glycosylation profile either in stroma or in epithelial cells. Furthermore, in vivo studies (using Azoxymethane (AOM)/dextran sodium sulphate (DSS) to induce CAC) were conducted in MGAT5 wild-type and null mice. The combined glycoimmune profile of colonic cells was analysed by flow cytometry. Analysis of RNAseq data from colitis-associated cancer mice model (the AOM/DSS mouse model) was performed to decipher the glyco-fingerprint in colonic cells during colitis; low- and high-grade dysplasia and adenocarcinoma. Results: Our cross-sectional study revealed a distinct glycoprofile in stroma, characterised by a decreased expression of branched N-glycans in colitis followed by increased expression in dysplasia and colon carcinoma stages corroborated by the RNASeq analysis on the colon of AOM/DSS mouse model. Additionally, colonic T cells isolated from both AOM/DSS MGAT5 WT and KO mice presented a distinct glycoprofile along CAC development. Conclusion: Our preliminary results both from human and mice samples demonstrate a distinct glycoimmuno profile along the colitis-associated carcinoma cascade, which potentially represents a biomarker to early identify risk UC patients.
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S012-S013
OP13 Glyco-fingerprint as a relevant risk factor on colitis-associated cancer
Background: Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract being considered a serious risk factor for the development of colitis-associated cancer (CAC). However, the molecular mechanisms underlying CAC progression are still elusive. We previously showed that decreased expression of MGAT5 glycogene on intestinal T lymphocytes from UC patients was associated with a hyperimmune response and with disease severity (Dias, AM et al. HMG,2014; Dias, AM et al. PNAS, 2018). On the other hand, we also demonstrated that the aberrant expression of MGAT5 glycogene in gastrointestinal cancer cells was associated with tumour invasiveness and progression (Carvalho S et al., Oncogene 2015). However, whether this differential expression of glycans in colitis and cancer contexts mediated by MGAT5 glycogene constitutes a new mechanism in CAC remains completely unknown. Methods: A well-characterised cohort of paraffin samples from CAC patients at different stages of carcinogenesis (colitis; dysplasia and colon cancer) were evaluated by immunohistochemistry, using specific lectins to evaluate the N-glycosylation profile either in stroma or in epithelial cells. Furthermore, in vivo studies (using Azoxymethane (AOM)/dextran sodium sulphate (DSS) to induce CAC) were conducted in MGAT5 wild-type and null mice. The combined glycoimmune profile of colonic cells was analysed by flow cytometry. Analysis of RNAseq data from colitis-associated cancer mice model (the AOM/DSS mouse model) was performed to decipher the glyco-fingerprint in colonic cells during colitis; low- and high-grade dysplasia and adenocarcinoma. Results: Our cross-sectional study revealed a distinct glycoprofile in stroma, characterised by a decreased expression of branched N-glycans in colitis followed by increased expression in dysplasia and colon carcinoma stages corroborated by the RNASeq analysis on the colon of AOM/DSS mouse model. Additionally, colonic T cells isolated from both AOM/DSS MGAT5 WT and KO mice presented a distinct glycoprofile along CAC development. Conclusion: Our preliminary results both from human and mice samples demonstrate a distinct glycoimmuno profile along the colitis-associated carcinoma cascade, which potentially represents a biomarker to early identify risk UC patients.
- Open Access
- 1 January 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (1) , 95-110
Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases
- 1 January 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (1) , 95-110
Open AccessProtein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases
- Open Access
- 27 November 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2754
Glycans as Key Checkpoints of T Cell Activity and Function
The immune system is highly controlled and fine-tuned by glycosylation, through the addition of a diversity of carbohydrates structures (glycans) to virtually all immune cell receptors. Despite a relative backlog in understanding the importance of glycans in the immune system, due to its inherent complexity, remarkable findings have been highlighting the essential contributions of glycosylation in the regulation of both innate and adaptive immune responses with important implications in the pathogenesis of major diseases such as autoimmunity and cancer. Glycans are implicated in fundamental cellular and molecular processes that regulate both stimulatory and inhibitory immune pathways. Besides being actively involved in pathogen recognition through interaction with glycan-binding proteins (such as C-type lectins), glycans have been also shown to regulate key pathophysiological steps within T cell biology such as T cell development and thymocyte selection; T cell activity and signaling as well as T cell differentiation and proliferation. These effects of glycans in T cells functions highlight their importance as determinants of either self-tolerance or T cell hyper-responsiveness which ultimately might be implicated in the creation of tolerogenic pathways in cancer or loss of immunological tolerance in autoimmunity. This review discusses how specific glycans (with a focus on N-linked glycans) act as regulators of T cell biology and their implications in disease.
- 27 November 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2754
Open AccessGlycans as Key Checkpoints of T Cell Activity and Function
The immune system is highly controlled and fine-tuned by glycosylation, through the addition of a diversity of carbohydrates structures (glycans) to virtually all immune cell receptors. Despite a relative backlog in understanding the importance of glycans in the immune system, due to its inherent complexity, remarkable findings have been highlighting the essential contributions of glycosylation in the regulation of both innate and adaptive immune responses with important implications in the pathogenesis of major diseases such as autoimmunity and cancer. Glycans are implicated in fundamental cellular and molecular processes that regulate both stimulatory and inhibitory immune pathways. Besides being actively involved in pathogen recognition through interaction with glycan-binding proteins (such as C-type lectins), glycans have been also shown to regulate key pathophysiological steps within T cell biology such as T cell development and thymocyte selection; T cell activity and signaling as well as T cell differentiation and proliferation. These effects of glycans in T cells functions highlight their importance as determinants of either self-tolerance or T cell hyper-responsiveness which ultimately might be implicated in the creation of tolerogenic pathways in cancer or loss of immunological tolerance in autoimmunity. This review discusses how specific glycans (with a focus on N-linked glycans) act as regulators of T cell biology and their implications in disease.
- 1 November 2018
- Published by Elsevier in Cellular Immunology
- Vol. 333, 9-18
Glycans as critical regulators of gut immunity in homeostasis and disease
- 1 November 2018
- Published by Elsevier in Cellular Immunology
- Vol. 333, 9-18
Glycans as critical regulators of gut immunity in homeostasis and disease
- 20 September 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (1) , 39-49
A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients
There is a clinical need to identify biomarkers able to select patients who are most likely to develop aggressive/complicated disease and early select them for appropriate therapy. Changes in the glycosylation profile of intestinal lymphocytic infiltrate was previously demonstrated to regulate T cell activity being associated with disease severity in ulcerative colitis (UC) patients. We interrogated whether this heterogeneous expression of branched N-glycans on intestinal inflammatory infiltrate predict therapy response early in disease course. The expression levels of the branched N-glycans in colonic biopsies collected around time of diagnosis from a well-characterized cohort of 131 UC patients were correlated with response to standard therapy. ROC analysis and specificity/sensitivity were determined. Branched N-glycans levels around time of diagnosis predict non-response to conventional therapy with 75% of specificity. Moreover, high levels of branched N-glycans predict 78% of UC patients that will display a favorable disease course (exclusively under 5-ASA therapy with more than 5 years the disease). The best predictive performance was observed in severe UC patients with Mayo endoscopic subsore 3 and in those that were naïve for therapy. Multivariable analysis revealed that low levels of branched N-glycans and high levels of C Reactive Protein (CRP) around time of diagnosis act as independent predictors of non-response to standard therapy. A powerful effect of the combined use of the branched N-glycans and CRP was observed. Our results reveal a potential (glyco)biomarker that predicts, early in the disease course, patients that will fail to respond to standard therapy, benefiting thereby from other therapeutic strategies as biologics.
- 20 September 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (1) , 39-49
A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients
There is a clinical need to identify biomarkers able to select patients who are most likely to develop aggressive/complicated disease and early select them for appropriate therapy. Changes in the glycosylation profile of intestinal lymphocytic infiltrate was previously demonstrated to regulate T cell activity being associated with disease severity in ulcerative colitis (UC) patients. We interrogated whether this heterogeneous expression of branched N-glycans on intestinal inflammatory infiltrate predict therapy response early in disease course. The expression levels of the branched N-glycans in colonic biopsies collected around time of diagnosis from a well-characterized cohort of 131 UC patients were correlated with response to standard therapy. ROC analysis and specificity/sensitivity were determined. Branched N-glycans levels around time of diagnosis predict non-response to conventional therapy with 75% of specificity. Moreover, high levels of branched N-glycans predict 78% of UC patients that will display a favorable disease course (exclusively under 5-ASA therapy with more than 5 years the disease). The best predictive performance was observed in severe UC patients with Mayo endoscopic subsore 3 and in those that were naïve for therapy. Multivariable analysis revealed that low levels of branched N-glycans and high levels of C Reactive Protein (CRP) around time of diagnosis act as independent predictors of non-response to standard therapy. A powerful effect of the combined use of the branched N-glycans and CRP was observed. Our results reveal a potential (glyco)biomarker that predicts, early in the disease course, patients that will fail to respond to standard therapy, benefiting thereby from other therapeutic strategies as biologics.
- Open Access
- 4 June 2018
- Published by Springer Nature in Clinical Epigenetics
- Vol. 10 (1) , 1-14
Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease
Many genome- and epigenome-wide association studies (GWAS and EWAS) and studies of promoter methylation of candidate genes for inflammatory bowel disease (IBD) have demonstrated significant associations between genetic and epigenetic changes and IBD. Independent GWA studies have identified genetic variants in the BACH2, IL6ST, LAMB1, IKZF1, and MGAT3 loci to be associated with both IBD and immunoglobulin G (IgG) glycosylation. Using bisulfite pyrosequencing, we analyzed CpG methylation in promoter regions of these five genes from peripheral blood of several hundred IBD patients and healthy controls (HCs) from two independent cohorts, respectively. We found significant differences in the methylation levels in the MGAT3 and BACH2 genes between both Crohn’s disease and ulcerative colitis when compared to HC. The same pattern of methylation changes was identified for both genes in CD19+ B cells isolated from the whole blood of a subset of the IBD patients. A correlation analysis was performed between the MGAT3 and BACH2 promoter methylation and individual IgG glycans, measured in the same individuals of the two large cohorts. MGAT3 promoter methylation correlated significantly with galactosylation, sialylation, and bisecting GlcNAc on IgG of the same patients, suggesting that activity of the GnT-III enzyme, encoded by this gene, might be altered in IBD. The correlations between the BACH2 promoter methylation and IgG glycans were less obvious, since BACH2 is not a glycosyltransferase and therefore may affect IgG glycosylation only indirectly. Our results suggest that epigenetic deregulation of key glycosylation genes might lead to an increase in pro-inflammatory properties of IgG in IBD through a decrease in galactosylation and sialylation and an increase of bisecting GlcNAc on digalactosylated glycan structures. Finally, we showed that CpG methylation in the promoter of the MGAT3 gene is altered in CD3+ T cells isolated from inflamed mucosa of patients with ulcerative colitis from a third smaller cohort, for which biopsies were available, suggesting a functional role of this glyco-gene in IBD pathogenesis.
- 4 June 2018
- Published by Springer Nature in Clinical Epigenetics
- Vol. 10 (1) , 1-14
Open AccessPromoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease
Many genome- and epigenome-wide association studies (GWAS and EWAS) and studies of promoter methylation of candidate genes for inflammatory bowel disease (IBD) have demonstrated significant associations between genetic and epigenetic changes and IBD. Independent GWA studies have identified genetic variants in the BACH2, IL6ST, LAMB1, IKZF1, and MGAT3 loci to be associated with both IBD and immunoglobulin G (IgG) glycosylation. Using bisulfite pyrosequencing, we analyzed CpG methylation in promoter regions of these five genes from peripheral blood of several hundred IBD patients and healthy controls (HCs) from two independent cohorts, respectively. We found significant differences in the methylation levels in the MGAT3 and BACH2 genes between both Crohn’s disease and ulcerative colitis when compared to HC. The same pattern of methylation changes was identified for both genes in CD19+ B cells isolated from the whole blood of a subset of the IBD patients. A correlation analysis was performed between the MGAT3 and BACH2 promoter methylation and individual IgG glycans, measured in the same individuals of the two large cohorts. MGAT3 promoter methylation correlated significantly with galactosylation, sialylation, and bisecting GlcNAc on IgG of the same patients, suggesting that activity of the GnT-III enzyme, encoded by this gene, might be altered in IBD. The correlations between the BACH2 promoter methylation and IgG glycans were less obvious, since BACH2 is not a glycosyltransferase and therefore may affect IgG glycosylation only indirectly. Our results suggest that epigenetic deregulation of key glycosylation genes might lead to an increase in pro-inflammatory properties of IgG in IBD through a decrease in galactosylation and sialylation and an increase of bisecting GlcNAc on digalactosylated glycan structures. Finally, we showed that CpG methylation in the promoter of the MGAT3 gene is altered in CD3+ T cells isolated from inflamed mucosa of patients with ulcerative colitis from a third smaller cohort, for which biopsies were available, suggesting a functional role of this glyco-gene in IBD pathogenesis.
- Open Access
- 2 May 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (20) , E4651-E4660
Metabolic control of T cell immune response through glycans in inflammatory bowel disease
Significance: Our findings demonstrate that metabolic supplementation of mucosal T cells, isolated from patients with active ulcerative colitis (UC), with N -acetylglucosamine (GlcNAc) leads to the enhancement of branched N-glycosylation on the T cell receptor, which was associated with the control of T cell activation and function. These results were validated in “glycoengineered” mouse models with severe colitis. Overall, our results open new avenues for a targeted-specific therapy in inflammatory bowel disease (IBD). The therapeutic use of GlcNAc (either alone or in combination with other antiinflammatory therapies) represents a simple immunomodulatory strategy in IBD, with absence of side effects, low costs, and the possibility of being used as a simple rescue therapy to avoid unnecessary toxic effects and step-up therapies in IBD.
- 2 May 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (20) , E4651-E4660
Open AccessMetabolic control of T cell immune response through glycans in inflammatory bowel disease
Significance: Our findings demonstrate that metabolic supplementation of mucosal T cells, isolated from patients with active ulcerative colitis (UC), with N -acetylglucosamine (GlcNAc) leads to the enhancement of branched N-glycosylation on the T cell receptor, which was associated with the control of T cell activation and function. These results were validated in “glycoengineered” mouse models with severe colitis. Overall, our results open new avenues for a targeted-specific therapy in inflammatory bowel disease (IBD). The therapeutic use of GlcNAc (either alone or in combination with other antiinflammatory therapies) represents a simple immunomodulatory strategy in IBD, with absence of side effects, low costs, and the possibility of being used as a simple rescue therapy to avoid unnecessary toxic effects and step-up therapies in IBD.
- 22 November 2015
- Published by Springer Nature
- Vol. 1389, 167-176
Studying T Cells N-Glycosylation by Imaging Flow Cytometry
Imaging flow cytometry is an emerging imaging technology that combines features of both conventional flow cytometry and fluorescence microscopy allowing quantification of the imaging parameters. The analysis of protein posttranslational modifications by glycosylation using imaging flow cytometry constitutes an important bioimaging tool in the glycobiology field. This technique allows quantification of the glycan fluorescence intensity, co-localization with proteins, and evaluation of the membrane/cytoplasmic expression. In this chapter we provide the guidelines to analyze glycan expression, particularly the β1,6 GlcNAc branched N-glycans, on the membrane of intestinal T cells from inflammatory bowel disease patients.
- 22 November 2015
- Published by Springer Nature
- Vol. 1389, 167-176
Studying T Cells N-Glycosylation by Imaging Flow Cytometry
Imaging flow cytometry is an emerging imaging technology that combines features of both conventional flow cytometry and fluorescence microscopy allowing quantification of the imaging parameters. The analysis of protein posttranslational modifications by glycosylation using imaging flow cytometry constitutes an important bioimaging tool in the glycobiology field. This technique allows quantification of the glycan fluorescence intensity, co-localization with proteins, and evaluation of the membrane/cytoplasmic expression. In this chapter we provide the guidelines to analyze glycan expression, particularly the β1,6 GlcNAc branched N-glycans, on the membrane of intestinal T cells from inflammatory bowel disease patients.
- Open Access
- 20 July 2015
- Published by Springer Nature in Oncogene
- Vol. 35 (13) , 1619-1631
Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer
E-cadherin is a central molecule in the process of gastric carcinogenesis and its posttranslational modifications by N-glycosylation have been described to induce a deleterious effect on cell adhesion associated with tumor cell invasion. However, the role that site-specific glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined. Using transgenic mice models and human clinical samples, we demonstrated that N-acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation causes an abnormal pattern of E-cadherin expression in the gastric mucosa. In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V. This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell–cell aggregation, which was further observed in human gastric carcinomas. Interestingly, manipulating this site-specific glycosylation, by preventing Asn-554 from receiving the deleterious branched structures, either by a mutation or by silencing GnT-V, resulted in a protective effect on E-cadherin, precluding its functional dysregulation and contributing to tumor suppression.
- 20 July 2015
- Published by Springer Nature in Oncogene
- Vol. 35 (13) , 1619-1631
Open AccessPreventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer
E-cadherin is a central molecule in the process of gastric carcinogenesis and its posttranslational modifications by N-glycosylation have been described to induce a deleterious effect on cell adhesion associated with tumor cell invasion. However, the role that site-specific glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined. Using transgenic mice models and human clinical samples, we demonstrated that N-acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation causes an abnormal pattern of E-cadherin expression in the gastric mucosa. In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V. This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell–cell aggregation, which was further observed in human gastric carcinomas. Interestingly, manipulating this site-specific glycosylation, by preventing Asn-554 from receiving the deleterious branched structures, either by a mutation or by silencing GnT-V, resulted in a protective effect on E-cadherin, precluding its functional dysregulation and contributing to tumor suppression.
- Open Access
- 30 May 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (5) , e98595
Pancreatic Cancer Cell Glycosylation Regulates Cell Adhesion and Invasion through the Modulation of α2β1 Integrin and E-Cadherin Function
In our previous studies we have described that ST3Gal III transfected pancreatic adenocarcinoma Capan-1 and MDAPanc-28 cells show increased membrane expression levels of sialyl-Lewis x (SLex) along with a concomitant decrease in α2,6-sialic acid compared to control cells. Here we have addressed the role of this glycosylation pattern in the functional properties of two glycoproteins involved in the processes of cancer cell invasion and migration, α2β1 integrin, the main receptor for type 1 collagen, and E-cadherin, responsible for cell-cell contacts and whose deregulation determines cell invasive capabilities. Our results demonstrate that ST3Gal III transfectants showed reduced cell-cell aggregation and increased invasive capacities. ST3Gal III transfected Capan-1 cells exhibited higher SLex and lower α2,6-sialic acid content on the glycans of their α2β1 integrin molecules. As a consequence, higher phosphorylation of focal adhesion kinase tyrosine 397, which is recognized as one of the first steps of integrin-derived signaling pathways, was observed in these cells upon adhesion to type 1 collagen. This molecular mechanism underlies the increased migration through collagen of these cells. In addition, the pancreatic adenocarcinoma cell lines as well as human pancreatic tumor tissues showed colocalization of SLex and E-cadherin, which was higher in the ST3Gal III transfectants. In conclusion, changes in the sialylation pattern of α2β1 integrin and E-cadherin appear to influence the functional role of these two glycoproteins supporting the role of these glycans as an underlying mechanism regulating pancreatic cancer cell adhesion and invasion.
- 30 May 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (5) , e98595
Open AccessPancreatic Cancer Cell Glycosylation Regulates Cell Adhesion and Invasion through the Modulation of α2β1 Integrin and E-Cadherin Function
In our previous studies we have described that ST3Gal III transfected pancreatic adenocarcinoma Capan-1 and MDAPanc-28 cells show increased membrane expression levels of sialyl-Lewis x (SLex) along with a concomitant decrease in α2,6-sialic acid compared to control cells. Here we have addressed the role of this glycosylation pattern in the functional properties of two glycoproteins involved in the processes of cancer cell invasion and migration, α2β1 integrin, the main receptor for type 1 collagen, and E-cadherin, responsible for cell-cell contacts and whose deregulation determines cell invasive capabilities. Our results demonstrate that ST3Gal III transfectants showed reduced cell-cell aggregation and increased invasive capacities. ST3Gal III transfected Capan-1 cells exhibited higher SLex and lower α2,6-sialic acid content on the glycans of their α2β1 integrin molecules. As a consequence, higher phosphorylation of focal adhesion kinase tyrosine 397, which is recognized as one of the first steps of integrin-derived signaling pathways, was observed in these cells upon adhesion to type 1 collagen. This molecular mechanism underlies the increased migration through collagen of these cells. In addition, the pancreatic adenocarcinoma cell lines as well as human pancreatic tumor tissues showed colocalization of SLex and E-cadherin, which was higher in the ST3Gal III transfectants. In conclusion, changes in the sialylation pattern of α2β1 integrin and E-cadherin appear to influence the functional role of these two glycoproteins supporting the role of these glycans as an underlying mechanism regulating pancreatic cancer cell adhesion and invasion.